Sol-Gel Technologies Ltd. Ordinary Shares (SLGL)

FairStock Score: 47/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Sol-Gel as a Graham-style analyst: what is proven, what is paid for, and what is the margin of safety? The company sells two topical dermatology creams, Twyneo and Epsolay, and has a Phase 3 candidate, SGT-610, with only 28 employees. In fiscal Q2 2026, revenue was $591,000 and net income was -$3.7 million, producing a -622.84% margin. That is not a durable moat; it is a small specialty pharma dependent on commercial execution and clinical success. The growth trajectory is deeply negative based on those filed quarter figures. Financial health is mixed. The FairStock debt-to-equity calculation is just 0.02, and its Altman Z-score is 18.65, which suggests low balance-sheet distress. But the FairStock Piotroski F-score is 3/9, ROE is -40.85%, and ROCE is -23.87%. At the 2026-10-13 close of $68.30, the market capitalization is $228.5 million. The FairStock P/B is 4.65, and the P/E is -12.15 because earnings are negative. A negative P/E does not make a bargain. The FairStock Score is 47/100. No Lynch category is assigned because there are only 0 years of filed results, not the 3 needed. This looks speculative. Low debt buys time, but with quarterly revenue of $591,000, time is not the same as value. I would need sustained sales and a path to positive cash generation before calling this a Graham-style investment.

In plain English: Sol-Gel Technologies makes prescription skin creams for acne and rosacea and is testing another skin treatment. The business looks weak right now: it is losing money and sales are very small. At $68.30, the stock looks expensive compared with its tiny sales and losses, even though it has little debt.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer